0001104659-22-057576.txt : 20220609 0001104659-22-057576.hdr.sgml : 20220609 20220509163519 ACCESSION NUMBER: 0001104659-22-057576 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 CORRESP 1 filename1.htm

 

Cara Therapeutics, Inc.

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut 06902

 

May 9, 2022

 

Via EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:   Michael Davis
   
Re:   Cara Therapeutics, Inc.
    Registration Statement on Form S-3 (File No. 333-263165), as amended by Amendment No. 1
   

Request for Acceleration of Effective Date

 

  Acceleration Request    
  Requested Date:   May 11, 2022
  Requested Time:   4:00 p.m. Eastern Time

 

Mr. Davis:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-263165), as amended by Amendment No. 1 (the “Registration Statement”) to become effective on May 11, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.

 

Once the Registration Statement has been declared effective, please orally confirm that event with Darren DeStefano of Cooley LLP, counsel to the Registrant, at (703) 456-8034.

 

[Signature page follows]

 

 

 

  Very truly yours,
   
  Cara Therapeutics, Inc.
     
  By:

/s/ Christopher Posner

    Christopher Posner
    Chief Executive Officer and Director

 

 

cc: Christopher Posner, Cara Therapeutics, Inc.

Darren DeStefano, Cooley LLP

 

  

 

Signature Page to Company Acceleration Request – S-3